Year: 2020

Tammi-syyskuun 2020 liikevaihto heikkeni ja liiketulos parani edellisen vuoden vastaavaan ajankohtaan verrattuna.Heinä-syyskuu 2020 Liikevaihto oli 24,2 MEUR (25,9), muutos -6,9 % Liiketulos oli 1,0 MEUR (1,0)Liikevoittoprosentti oli 4,3 % (4,0 %)Tilikauden tulos oli 0,7 MEUR (0,9)Osakekohtainen tulos oli 0,16 euroa (0,22)Tammi-syyskuu 2020Liikevaihto oli 66,5 MEUR (76,3), muutos -13,0 % Liiketulos oli -1,8 MEUR (-2,6)Liikevoittoprosentti oli -2,7 % (-3,4 %)Tilikauden tulos oli -2,7 MEUR (-3,0)Osakekohtainen tulos oli -0,65 euroa (-0,73)NäkymätNäkymät vuodelle 2020 Martela-konsernin koko vuoden 2020 liikevaihdon arvioidaan heikkenevän selvästi ja liiketuloksen heikkenevän edellisvuotisesta.Avainluvut, MeurToimitusjohtaja Artti Aurasmaa:”Liikevaihtomme laski vuoden kolmannella vuosineljänneksellä 6,9 % ja oli 24,2 milj. euroa. Kolmannen...

Hexagon Purus has signed a contract with Stadler Rail to develop cylinder storage system for the first hydrogen commuter train in the U.S.The contract includes the development and homologation of a new cylinder and tank system to be approved in the U.S. The train will be built and tested in Switzerland and other European locations, then transferred to California in 2023.“In the midst of the climate crisis, the demand for solutions that help reduce emissions across transport industries is growing rapidly. Hydrogen-powered trains are a smart solution to reduce local emissions without incurring the high cost of electrifying the tracks,” says Michael Kleschinski, Executive Vice President of Hexagon Purus. “We are pleased to help with the further development of the infrastructure need for this ground-breaking move in public transit.”About...

Revenues rose to $86.9 million, up 16.8% y-o-yComparable store sales up 13.5% y-o-yAdjusted EBITDA up 140.8% and on a per diluted share basis up by 141.3% y-o-y Launched new websites and iPhone applications as part of the omnichannel strategy featuring online booking capability, virtual optician appointment and bespoke frame ordersContinued integration of new technology to further elevate safety in stores and clinics in light of COVID-19MONTREAL, Nov. 05, 2020 (GLOBE NEWSWIRE) — New Look Vision Group Inc. (“New Look Vision” or the “Company”) (TSX: BCI), a leader in the Canadian retail optical industry with stores across Canada and in Florida, reported financial results today for the 13 and 39 week periods ended September 26, 2020 (“Q3 2020”) and provided updates on actions in response to COVID-19, store re-openings,...

Le chiffre d’affaires augmente de 16,8 % sur 12 mois pour s’établir à 86,9 millions $ Les ventes des magasins comparables progressent de 13,5 % sur 12 moisLe BAIIA ajusté bondit de 140,8 % et, sur une base diluée, de 141,3 % sur 12 moisLa société lance ses nouveaux sites Webs et ses nouvelles applications iPhone qui, conformément à sa stratégie omnicanal, permettent la prise de rendez-vous d’opticien en ligne et la commande de montures sur mesureL’intégration de nouvelles technologies se poursuit afin d’améliorer la sécurité dans les magasins et les cliniques malgré la COVID-19 MONTRÉAL, 05 nov. 2020 (GLOBE NEWSWIRE) — Groupe Vision New Look Inc. (« Vision New Look » ou la « société ») (TSX: BCI), un chef de file dans la vente au détail dans l’industrie de l’optique au Canada avec ses magasins au Canada et en Floride, a annoncé...

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 05, 2020 (GLOBE NEWSWIRE) — AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that David McIntyre notified the Company of his intention to resign as the Company’s Chief Financial Officer in order to pursue life sciences opportunities in his home state of New Jersey. The effective date of his resignation is November 23, 2020. Mr. McIntyre has also agreed to provide consultancy services to the Company through December 31, 2020 so as to support a smooth transition of his responsibilities. The Company wishes to thank David for successfully leading and completing the redomiciliation project during his...

TORONTO, Nov. 05, 2020 (GLOBE NEWSWIRE) — Noranda Income Fund (TSX:NIF.UN) (the “Fund”) today reported its financial results for the third quarter ended September 30, 2020. The Fund also announced the extension of its exclusive agreements with Glencore Canada for the purchase of zinc concentrate and the sale of zinc metal for an additional period of three years through to April 30, 2025. In addition, the Supply and Processing Agreement (“SPA”) non-renewal notice period has been amended to 540 days before April 30, 2025 or any subsequent renewal date thereafter, an increase from the 180 days required by the original agreement. Except where otherwise indicated, all amounts in this press release are expressed in US dollars.Third Quarter 2020 HighlightsLoss before income taxes was $4.1 million in the third quarter of 2020 compared to...

TORONTO, 05 nov. 2020 (GLOBE NEWSWIRE) — Le Fonds de revenu Noranda (TSX : NIF.UN) (le « Fonds ») a annoncé aujourd’hui ses résultats financiers pour le troisième trimestre clos le 30 septembre 2020. De plus, le Fonds a annoncé la prolongation de ses conventions avec Glencore Canada visant l’exclusivité de l’achat de concentré et la vente de zinc pour une période supplémentaire de trois ans, soit jusqu’au 30 avril 2025. De plus, la période d’avis de non-renouvellement de la convention d’approvisionnement et de traitement (« CAT ») a été modifiée pour passer à 540 jours avant le 30 avril 2025 ou à toute autre date de renouvellement ultérieure par la suite, soit une augmentation par rapport aux 180 jours requis par la convention initiale. À moins d’indication contraire, tous les montants figurant dans le présent communiqué de presse...

Merger completed with Rexahn Pharmaceuticals creating a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug CandidatesTrading under “OCUP” on the Nasdaq Capital Market to begin November 6, 2020Concurrent $21.15 Million Private Placement led by Institutional Healthcare and Accredited InvestorsConference Call and Live Webcast on Friday, November 6, 2020, at 11 AM Eastern TimeFARMINGTON HILLS, Mich., Nov. 05, 2020 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, is pleased to announce the completion of its previously announced merger with Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN). The combined company will operate...